Eli Lilly and Company (LLY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Eli Lilly and Company (LLY) is Moderate Outperform.

The composite score behind that read is +0.36, weighing +0.43 of bullish evidence against -0.03 bearish.

Eli Lilly and Company last closed at $1,179.27, +0.83% on the session.

Against the IVW growth benchmark the position is +0.03% over the forecast window.

The read is built from 15 underlying insights — 13 bullish and 2 bearish.

Agreement across those insights is 87%.

5 graded predictions for LLY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Eli Lilly and Company in the 20th percentile on valuation and the 95th percentile on return on equity, where 100 is best.

Eli Lilly and Company is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.10T.

StockMap tracks Eli Lilly and Company as the 1st largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Eli Lilly and Company ranks 2nd of 151 in the group, against a group median of -0.08.